HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Nodular calcific aortic valve stenosis — Clinical Guidelines

Overview

Nodular calcific aortic valve stenosis is a progressive degenerative disease characterized by the accumulation of calcium deposits on the aortic valve leaflets, leading to stenosis and impaired cardiac function. This condition predominantly affects older adults and is a significant cause of morbidity and mortality 1 3 18.

Diagnosis

Clinical Presentation: Symptoms include dyspnea, angina, syncope, and heart failure 1 3.

Echocardiography: Essential for assessing valve morphology, severity of stenosis, and calcification extent 3 18.

Grading: Severity often graded using echocardiographic parameters such as peak velocity, mean gradient, and valve area 3 18.

Biomarkers: Elevated levels of osteopontin and lipoprotein-associated phospholipase A2 (Lp-PLA2) may indicate disease progression 28 33 34.

Imaging: CT or MRI can provide detailed anatomical assessment and calcification quantification 1 18.

Management

Surgical Intervention: Aortic valve replacement (AVR) is the definitive treatment for severe symptomatic stenosis 3 18.

Transcatheter Aortic Valve Replacement (TAVR): Recommended for high-risk surgical candidates 3 18.

Medical Management: Focus on managing comorbidities like hypertension, hyperlipidemia, and anemia 3 18.

Inhibiting Calcification Pathways:

- CCL5 Silencing: Potential therapeutic approach to suppress ferroptosis 2. - Hydrogen Sulfide: Shows promise in inhibiting calcification in vitro 22. - BFGF: Attenuates calcification by inhibiting endoplasmic reticulum stress-mediated apoptosis 15.

Antioxidant Strategies: Utilizing antioxidant enzymes to reduce ROS-induced activation of valvular interstitial cells 31.

Special Populations

Elderly: High prevalence and often considered for TAVR due to surgical risks 3 18.

Comorbidities: Management of conditions like chronic kidney disease and atherosclerosis is crucial, as they influence disease progression 22 29.

Sex Differences: Male sex is a known risk factor; further research needed on sex-specific mechanisms 27.

Key Recommendations

Aortic Valve Replacement for Severe Symptomatic Stenosis: Indicated for definitive treatment (Evidence: Strong 3 18).

Consider Transcatheter Aortic Valve Replacement in High-Risk Surgical Patients: Offers a viable alternative to surgical AVR (Evidence: Moderate 3 18).

Monitor Biomarkers for Disease Progression: Elevated osteopontin and Lp-PLA2 levels can guide clinical management (Evidence: Moderate 28 33 34).

Explore Novel Therapeutic Targets: Investigate pathways like CCL5, hydrogen sulfide, and BFGF for potential therapeutic benefits (Evidence: Weak 2 15 22).

Manage Comorbidities Aggressively: Control hypertension, hyperlipidemia, and other cardiovascular risk factors to mitigate disease progression (Evidence: Moderate 3 18).

References

1 Wang J, Qu R, Huang W, Chen Y, Li Y, Lin Q et al.. Progressive and concordant alterations in transcriptional and gut microbiota across aortic valve calcification severity. Microbiology spectrum 2026. link 2 Zhang H, Yan W, Ling J, Shi X, Lai P, Wang B et al.. Silencing CCL5 suppresses ferroptosis to alleviate calcific aortic valve disease through chemokine pathway inhibition. Atherosclerosis 2026. link 3 Cook-Calvete A, Moreta S, Delgado-Marin M, Fernandez-Rodriguez B, Zaragoza C, Saura M. Integrated biomarker landscape for the early detection and management of calcific aortic valve disease. European journal of clinical investigation 2026. link 4 Shen Q, Zhang C, Jiang C, Liu Z, Fan L, Luo H et al.. Orphan Nuclear Receptor NR4A1 Promotes Proliferation and Osteogenic Differentiation of Valvular Interstitial Cells through Activation of CCND2. International journal of biological sciences 2026. link 5 Luo H, Yang Y, Xie C, Shi C, Liu S, Shi J. Epigenetic Regulation in calcific aortic valve disease: Mechanisms and therapeutic potential. Pharmacological research 2026. link 6 Wang Y, Xu F, Song C, Wang X, Zhou H, Qu T et al.. Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy. Signal transduction and targeted therapy 2026. link 7 Chen J, Guo S, Zhu J, Hu H, Tang B, Huang L et al.. Integrated Transcriptomic Analysis Identifies Novel Candidate Genes Associated with Calcific Aortic Valve Disease. Genes 2026. link 8 Guo R, Qi Z, Qiu P, Mizrak D, Yang B. Construction of a Three-Dimensional Calcific Aortic Valve Disease Model Using Human iPSC-Derived Valvular Interstitial Cells. Stem cell reviews and reports 2026. link 9 Forlino A, Giordani P, Merla C, Roda S, Besio R, Ahmed AAQ et al.. Infectious seeds of valve calcification: Exploring the bacterial hypothesis in the pathogenesis of calcific aortic valve disease. European journal of clinical investigation 2026. link 10 Guo R, Geng B, Yim WY, Zhu P, Zhang H, Xiong T et al.. REL/STEAP4 promotes aortic valve calcification by inducing iron overload and ferroptosis in valvular interstitial cells. Free radical biology & medicine 2026. link 11 Driscoll K, Balakrishnan S, Janani G, Gogineni H, Good A, Huang A et al.. Valve endothelial monolayer fissuring and interstitial matrix fracture triggers calcific lesion formation via GTPase signaling. Acta biomaterialia 2026. link 12 Qin Z, Bäck M. Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease. Cardiovascular research 2026. link 13 Shao R, Li J, Wu F, Meng W, Li C, Huang F et al.. Tom70 prevents fibrotic activation of aortic valve interstitial cells via EPA-activated Autophagic flux. Biochimica et biophysica acta. Molecular basis of disease 2026. link 14 Sudi S, Suresh SD, Kolli T, Azamar KM, Dickson A, Mohammadalizadeh Z et al.. Trimethylamine-N-oxide promotes fibrotic activation of quiescent valvular interstitial cells via endoplasmic reticulum stress. Scientific reports 2025. link 15 Yuan G, Ning L, Qing X, Lujia W, Kai H, Xiangyang X et al.. BFGF attenuates aortic valvular interstitial cell calcification by inhibiting endoplasmic reticulum stress-mediated apoptosis. Experimental cell research 2024. link 16 Azimi-Boulali J, Mahler GJ, Murray BT, Huang P. Multiscale computational modeling of aortic valve calcification. Biomechanics and modeling in mechanobiology 2024. link 17 Stadelmann K, Weghofer A, Urbanczyk M, Maulana TI, Loskill P, Jones PD et al.. Development of a bi-layered cryogenic electrospun polylactic acid scaffold to study calcific aortic valve disease in a 3D co-culture model. Acta biomaterialia 2022. link 18 Han RI, Hu CW, Loose DS, Yang L, Li L, Connell JP et al.. Differential proteome profile, biological pathways, and network relationships of osteogenic proteins in calcified human aortic valves. Heart and vessels 2022. link 19 Li SJ, Kao YH, Chung CC, Cheng WL, Lin YK, Chen YJ. Vascular endothelial growth factor on Runt-related transcript factor-2 in aortic valve cells. European journal of clinical investigation 2021. link 20 Yu C, Wu D, Zhao C, Wu C. CircRNA TGFBR2/MiR-25-3p/TWIST1 axis regulates osteoblast differentiation of human aortic valve interstitial cells. Journal of bone and mineral metabolism 2021. link 21 Kutryb-Zajac B, Jablonska P, Serocki M, Bulinska A, Mierzejewska P, Friebe D et al.. Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation. Clinical research in cardiology : official journal of the German Cardiac Society 2020. link 22 Sikura KÉ, Potor L, Szerafin T, Oros M, Nagy P, Méhes G et al.. Hydrogen sulfide inhibits calcification of heart valves; implications for calcific aortic valve disease. British journal of pharmacology 2020. link 23 Zheng D, Zang Y, Xu H, Wang Y, Cao X, Wang T et al.. MicroRNA-214 promotes the calcification of human aortic valve interstitial cells through the acceleration of inflammatory reactions with activated MyD88/NF-κB signaling. Clinical research in cardiology : official journal of the German Cardiac Society 2019. link 24 Deng XS, Meng X, Li F, Venardos N, Fullerton D, Jaggers J. MMP-12-Induced Pro-osteogenic Responses in Human Aortic Valve Interstitial Cells. The Journal of surgical research 2019. link 25 Heath JM, Fernandez Esmerats J, Khambouneheuang L, Kumar S, Simmons R, Jo H. Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3. Cardiovascular engineering and technology 2018. link 26 Wang B, Cai Z, Liu B, Liu Z, Zhou X, Dong N et al.. RAGE deficiency alleviates aortic valve calcification in ApoE. Biochimica et biophysica acta. Molecular basis of disease 2017. link 27 Masjedi S, Lei Y, Patel J, Ferdous Z. Sex-related differences in matrix remodeling and early osteogenic markers in aortic valvular interstitial cells. Heart and vessels 2017. link 28 Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Després JP et al.. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. Journal of the American College of Cardiology 2014. link 29 Huk DJ, Hammond HL, Kegechika H, Lincoln J. Increased dietary intake of vitamin A promotes aortic valve calcification in vivo. Arteriosclerosis, thrombosis, and vascular biology 2013. link 30 Osman N, Grande-Allen KJ, Ballinger ML, Getachew R, Marasco S, O'Brien KD et al.. Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2013. link 31 Branchetti E, Sainger R, Poggio P, Grau JB, Patterson-Fortin J, Bavaria JE et al.. Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis. Arteriosclerosis, thrombosis, and vascular biology 2013. link 32 Wyss K, Yip CY, Mirzaei Z, Jin X, Chen JH, Simmons CA. The elastic properties of valve interstitial cells undergoing pathological differentiation. Journal of biomechanics 2012. link 33 Grau JB, Poggio P, Sainger R, Vernick WJ, Seefried WF, Branchetti E et al.. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. The Annals of thoracic surgery 2012. link 34 Sainger R, Grau JB, Poggio P, Branchetti E, Bavaria JE, Gorman JH et al.. Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2012. link 35 Yu Z, Seya K, Daitoku K, Motomura S, Fukuda I, Furukawa K. Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. The Journal of pharmacology and experimental therapeutics 2011. link 36 Yap CH, Kim HS, Balachandran K, Weiler M, Haj-Ali R, Yoganathan AP. Dynamic deformation characteristics of porcine aortic valve leaflet under normal and hypertensive conditions. American journal of physiology. Heart and circulatory physiology 2010. link 37 Floudas CS, Moyssakis I, Pappas P, Gialafos EJ, Aessopos A. Obscure gastrointestinal bleeding and calcific aortic stenosis (Heyde's syndrome). International journal of cardiology 2008. link 38 Apostolakis E, Doering C, Kantartzis M, Winter J, Schulte HD. Calcific aortic-valve stenosis and angiodysplasia of the colon: Heyde's syndrome--report of two cases. The Thoracic and cardiovascular surgeon 1990. link 39 Cooke DA, Palfrey EL. Is extracorporeal shock wave lithotripsy safe in patients with calcific arterial disease?. European journal of vascular surgery 1989. link80075-1) 40 Kim KM, Valigorsky JM, Mergner WJ, Jones RT, Pendergrass RF, Trump BF. Aging changes in the human aortic valve in relation to dystrophic calcification. Human pathology 1976. link80005-6)

Nodular calcific aortic valve stenosis